Items Tagged ‘Opdivo’


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Opdivo News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Head and Neck Cancer-What You Need to Know

August 14, 2017

Head and Neck Cancer-What You Need to Know

By cancerconnect cancerconnect

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck cancers account for about 3 percent of […]

View full entry

Tags: checkpoint inhibitors, Head and Neck Cancer, human papilloma virus, keytruda, News Tips and Features, News Tips and Features Other, Opdivo, PD-1


Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer

May 18, 2017

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer

By Anonymous User anonymous_user_10987

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with liver cancer, regardless of whether or not patients were infected with Hepatitis B or C.  These study results were […]

View full entry

Tags: CheckMate 040 nivolumab, immuno-oncology, Liver Cancer, News Tips and Features, News Tips and Features Other, Opdivo, PD-1, Precision Cancer Medicine


Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

February 6, 2017

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

By Anonymous User anonymous_user_10987

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments. About Gastric Cancer Gastric cancer refers to cancer of the […]

View full entry

Tags: Gastric Cancer, immunotherapy, News Tips and Features, News Tips and Features Other, nivolumab, Opdivo, precision medicine


Opdivo® Improves Survival in Advanced Stomach Cancer

November 22, 2016

Opdivo® Improves Survival in Advanced Stomach Cancer

By megm megm

The immune-stimulating agent Opdivo® (nivolumab) appears to significantly improve overall survival among patients with advanced stomach cancer for which no standard treatment options exist. Opdivo is not yet approved for stomach cancer. Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, News Tips and Features, News Tips and Features Other, nivolumab, Opdivo, stomach cancer


View more articles like this
More news and in-depth Gastric Cancer information

CONDITIONS OF THE GI TRACT